Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02606253
Recruitment Status : Completed
First Posted : November 17, 2015
Results First Posted : November 8, 2019
Last Update Posted : November 8, 2019
Sponsor:
Information provided by (Responsible Party):
Zachary L. Cox, Vanderbilt University

Brief Summary:

Broad Objectives: To determine the comparative efficacy of commonly employed strategies to overcome loop diuretic resistance when added to concomitant loop diuretics in hospitalized decompensated heart failure patients with hypervolemia

Specific Aims:

  1. Compare the 48-hour weight change of either intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in decompensated heart failure
  2. Compare the adverse effects of electrolyte depletion and renal function changes between intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure
  3. Pharmacoeconomic analysis of the direct costs of intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure

The investigators will conduct a dual center, randomized, double-blind, double-dummy, parallel design trial comparing: oral metolazone, intravenous chlorothiazide, or oral tolvaptan, in combination with loop diuretics in 60 patients hospitalized for hypervolemic decompensated heart failure and displaying loop diuretic resistance.


Condition or disease Intervention/treatment Phase
Heart Failure Drug: tolvaptan Drug: Chlorothiazide Drug: Metolazone Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Oral Thiazides vs Intravenous Thiazides vs Tolvaptan in Combination With Loop Diuretics for Diuretic Resistant Decompensated Heart Failure
Study Start Date : February 2016
Actual Primary Completion Date : September 27, 2018
Actual Study Completion Date : October 31, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Metolazone
Metolazone 5mg tablet orally twice daily for 48 hours.
Drug: Metolazone
Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
Other Name: Zaroxolyn

Experimental: Chlorothiazide
Chlorothiazide 500mg intravenous infusion over 30 minutes twice daily for 48 hours
Drug: Chlorothiazide
Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
Other Name: Diuril

Experimental: Tolvaptan
Tolvaptan 30mg tablet orally once daily for 48 hours
Drug: tolvaptan
Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
Other Name: Samsca




Primary Outcome Measures :
  1. Weight Change Over 48 Hours [ Time Frame: 48 hours ]
    The primary outcome will be 48-hour standing scale weight change (kg) from enrollment among the metolazone, intravenous chlorothiazide, and tolvaptan arms, using metolazone group as the comparator group for all other groups.


Secondary Outcome Measures :
  1. Net Urine Output [ Time Frame: 48 hours ]
    Net urine output from enrollment to the end of study at 48 hours measured in liters

  2. Mean Change in Serum Creatinine [ Time Frame: 48 hours ]
    Mean change in serum creatinine (mg/dl) from enrollment to end of study at 48 hours

  3. Mean Change in Glomerular Filtration Rate at Discharge [ Time Frame: hospital discharge an average of 5 days ]
    Mean change in glomerular filtration rate from enrollment to end of study at hospital discharge, an average of 5 days

  4. Mean Change in Serum Potassium [ Time Frame: 48 hours ]
    Mean change in serum potassium (mEq/L) from enrollment to end of study at 48 hours

  5. Potassium Supplementation [ Time Frame: 48 hours ]
    Cumulative dose of potassium supplementation (mEq) administered from enrollment to end of study at 48 hours

  6. Number of Patients With Hypokalemia [ Time Frame: 48 hours ]
    Incidence of hypokalemia (serum potassium less than 3.5mEq/L ) from enrollment to end of study

  7. Number of Patients With Escalation of Loop Diuretic Therapy [ Time Frame: 24 hours ]
    Provider escalation of loop diuretic dosage at 24 hours for urine output less than 3 L at 24 hours

  8. Number of Patients With Cardiac Arrhythmias [ Time Frame: 48 hours ]
    Incidence of new atrial or ventricular arrhythmias from enrollment to end of study at 48 hours

  9. Number of Patients With Symptomatic Hypotension [ Time Frame: 48 hours ]
    SBP < 85 mmHg plus medical intervention for symptomatic hypotension

  10. Change in eGFR From Baseline to 48 Hours [ Time Frame: 48 hours ]
    Change in estimated glomerular filtration rate (ml/min/m2) from baseline to 48 hours

  11. Mean Change in Serum Sodium [ Time Frame: 48 hours ]
    Mean change in serum sodium (mEq/L) from enrollment to end of study at 48 hours


Other Outcome Measures:
  1. Number of Patients With In-hospital Mortality [ Time Frame: Enrollment to hospital discharge an average of 5 days ]
    Incidence of death from study enrollment to hospital discharge, an average of 5 days

  2. Number of Patients With New Inotrope Utilization [ Time Frame: 48 hours ]
    Incidence of new initiation of dopamine, dobutamine, or milrinone from enrollment to end of study at 48 hours

  3. Number of Patients With Renal Replacement Therapy Utilization [ Time Frame: enrollment to hospital discharge an average of 5 days ]
    Incidence of Renal replacement therapy utilization (hemodialysis, ultrafiltration) from enrollment to hospital discharge, an average of 5 days

  4. Diuretic Efficiency [ Time Frame: 48 hours ]
    Diuretic Efficiency is calculated as 48hr urine output/ 48hr Furosemide equivalents in milligrams

  5. Change in Serum Chloride From Baseline [ Time Frame: 48 hours ]
    Change in serum chloride (mEq/L) from baseline to 48 hrs

  6. Change in Patient Congestion Score [ Time Frame: 48 hours ]
    Participants will score their congestion on a 10cm scale ranging from "Best" (10cm) to "Worst" (0cm). Change in score (units in centimeters) from baseline to 48 hours.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age of 18 years or older
  • hospital admission for hypervolemic decompensated heart failure complicated by loop diuretic resistance
  • 24 hour telemetry monitoring on an inpatient ward
  • basic metabolic panel laboratory assessment twice daily during the study period

Hypervolemia will be diagnosed by the admitting provider as either (i) pulmonary artery catheterization with a pulmonary capillary wedge pressure greater than 19mmHg plus a systemic physical exam finding of hypervolemia (peripheral edema, ascites, or pulmonary edema on auscultation) or (ii) in the absence of pulmonary artery catheterization data 2 of the following signs or symptoms: peripheral edema ascites, jugular venous pressure > 10mmHg, or pulmonary edema on chest x-ray.

Loop diuretic resistance is defined as a provider decision to pursue combination diuretic therapy because of failure to reach provider defined adequate diuresis (can not exceed urine output of 2 L in past 12 hours) despite receipt of an intravenous loop diuretic dose of a furosemide equivalent of at least 240mg/day over at least the past 12 hours (40mg furosemide = 20mg torsemide = 1mg bumetanide).

Exclusion Criteria:

  • decision to pursue hemodialysis by a nephrologist
  • estimated glomerular filtration rate by the MDRD equation < 15ml/min/m2
  • systolic blood pressure < 85mmHg
  • pregnancy
  • serum potassium < 3.0mEq/L
  • serum sodium > 145mEq/L or < 130mEq/L
  • severe malnutrition
  • advanced liver disease
  • inability to perform standing weights
  • inability to collect and measure urine with either a foley catheter or urine collection containers
  • concomitant therapy with strong CYP3A4 inhibitors/inducers (systemic ketoconazole, clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir, nefazodone, rifampin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, St. John's Wort)
  • concomitant therapy with p-glycoprotein inhibitors (cyclosporine, erythromycin, tacrolimus, dronedarone, quinidine, or verapamil)
  • non-study diuretics (spironolactone doses >75mg/day, eplerenone > 75mg/day, non-study thiazides or loop diuretics, or systemic acetazolamide, triamterene, or amiloride therapy)
  • thiazides administration in the previous 24 hours prior to randomization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02606253


Locations
Layout table for location information
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37204
Sponsors and Collaborators
Vanderbilt University
Investigators
Layout table for investigator information
Principal Investigator: Zachary L Cox, PharmD Vanderbilt University
  Study Documents (Full-Text)

Documents provided by Zachary L. Cox, Vanderbilt University:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Zachary L. Cox, Associate Professor, Lipscomb University College of Pharmacy, Vanderbilt University
ClinicalTrials.gov Identifier: NCT02606253    
Other Study ID Numbers: VU-IRB-TBD
First Posted: November 17, 2015    Key Record Dates
Results First Posted: November 8, 2019
Last Update Posted: November 8, 2019
Last Verified: October 2019
Keywords provided by Zachary L. Cox, Vanderbilt University:
loop diuretics
thiazide diuretics
vasopressin antagonists
diuretic resistance
heart failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Metolazone
Chlorothiazide
Tolvaptan
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs
Antihypertensive Agents
Diuretics
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators